Bremelanotide

Bremelanotide is a cyclic heptapeptide lactam analogue of α-melanocyte-stimulating hormone (α-MSH). Its chemical formula is C50H68N14O10, and it has a molar mass of approximately 1025.18 g/mol . The peptide sequence of Bremelanotide is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH .

Bremelanotide works by activating melanocortin receptors, specifically the MC4R receptor, which is involved in sexual arousal and desire . Unlike other treatments for sexual dysfunction, Bremelanotide does not act on the vascular system but rather on the central nervous system, making it unique in its approach .

Bremelanotide is used to treat generalized HSDD in premenopausal women. It is specifically recommended for those who experience low sexual desire that is not attributable to medical, psychiatric, or relationship problems . The medication is administered via subcutaneous injection, typically in the thigh or abdomen .

Common side effects of Bremelanotide include nausea, headache, and reactions at the injection site such as pain, redness, or itching . It may also cause a temporary increase in blood pressure and a decrease in heart rate after each dose . Additionally, some users may experience darkening of the gums, face, and breasts .

Bremelanotide was approved for medical use in the United States by the FDA in 2019 . It was developed by Palatin Technologies and is considered a first-in-class medication by the FDA .